For patients with ovarian cancer who are in remission, the probability of remaining disease-free improves considerably over time, and conditional disease-free survival might be a good estimate of ...
CHICAGO -- Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, ...
This is a preview. Log in through your library . Abstract Many studies have focused on white and black disparities in epithelial ovarian cancer (EOC) but fewer include Hispanics. Florida presents a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback